Amgen Inc.

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:01 2024-05-31 pm EDT			5-day change	1st Jan Change
305.8 ^USD	+1.59%		-0.01%	+6.17%

May. 28	US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	RE
May. 28	Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	DJ

US FDA approves Amgen drug for small cell lung cancer, Bloomberg News reports

May 16, 2024 at 03:13 pm EDT

May 16 (Reuters) - The U.S. Food and Drug Administration granted accelerated approval to tarlatamab, Amgen's targeted immunotherapy for treating adults with advanced small cell lung cancer that has worsened despite chemotherapy, Bloomberg News reported on Thursday. (Reporting By Deena Beasley; Editing by Bill Berkrot)

Latest news about Amgen Inc.

US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	May. 28	RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	May. 28	DJ
Weight-loss drug forecasts jump to $150 billion as supply grows	May. 28	RE
Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	May. 22	CF
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test	May. 22	MT
Transcript : Amgen Inc. - Special Call	May. 20
HSBC Adjusts Price Target on Amgen to $356 From $322	May. 20	MT
Amgen and AstraZeneca's Lung Disease Drug Study Reports Mixed Results	May. 20	MT
Amgen Announces the Results of the Phase 2a COURSE Trial Evaluating Tezspire® (Tezepelumab-Ekko) in People with Moderate to Very Severe Chronic Obstructive Pulmonary Disease	May. 19	CI
US FDA approves Amgen drug for small cell lung cancer	May. 17	RE
FDA Approves Amgen's IMDELLTRA?? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer	May. 16	CI
Amgen Gets FDA Approval for Small-Cell Lung-Cancer Treatment	May. 16	DJ
Amgen's Imdelltra Gets US FDA Accelerated Approval for Drug to Treat Extensive Stage Small Cell Lung Cancer	May. 16	MT
US FDA approves Amgen drug for small cell lung cancer, Bloomberg News reports	May. 16	RE
Transcript : Amgen Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM	May. 14
Redburn Adjusts Price Target on Amgen to $170 From $180, Keeps Sell Rating	May. 13	MT
ANALYST RECOMMENDATIONS : UBER, Luluemon, Airbnb, Progressive...	May. 09
Redburn Atlantic Adjusts Price Target on Amgen to $180 From $170	May. 09	MT
Mizuho Securities Raises Amgen's Price Target to $235 From $223	May. 08	MT
North American Morning Briefing : Stock Futures -2-	May. 06	DJ
News Highlights : Top Company News of the Day - Friday at 5 PM ET	May. 03	DJ
News Highlights : Top Company News of the Day - Friday at 7 PM ET	May. 03	DJ
Health Care Climbs as Amgen Surges on Obesity-Drug Plans - Health Care Roundup	May. 03	DJ
Apple Rally Helps Boost Equity Markets as Traders Parse Jobs Report	May. 03	MT
Apple Rally Helps Boost Equity Markets as Traders Parse Jobs Report	May. 03	MT

Chart Amgen Inc.

Duration

Period

More charts

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

Pharmaceuticals

Calendar

02:15pm - American Society of Clinical Oncology Meeting - Abstract No - 8512

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

305.8 USD

Average target price

316.3 USD

Spread / Average Target

+3.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AMGEN INC.	+6.17%	164B
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
PFIZER, INC.	-0.45%	162B
SANOFI	-.--%	122B

Other Pharmaceuticals

Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

US FDA approves Amgen drug for small cell lung cancer, Bloomberg News reports

EPS Revisions